Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.30 USD

55.30
4,824,228

+0.98 (1.80%)

Updated Nov 4, 2024 12:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

    Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

    by Zacks Equity Research

    Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.

      Upgraded Broker Ratings Make These 5 Stocks Worth Investing

      by Zacks Equity Research

      Broker advice helps to choose the right stocks as they have deeper insight into fundamentals.

        Arpita Dutt headshot

        5 Biotech and Pharma Stocks with Key FDA Catalysts this November

        by Arpita Dutt

        Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

          The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate

            Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss

            by Zacks Equity Research

            Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.

              Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

              by Zacks Equity Research

              With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?

                by Zacks Equity Research

                AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.

                  What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?

                  by Zacks Equity Research

                  The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.

                    What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

                    by Zacks Equity Research

                    Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                      Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat

                      by Zacks Equity Research

                      Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.

                        Company News For Oct 27, 2017

                        by Zacks Equity Research

                        Companies in the news are: TWTR,F,BMY,ABMD

                          Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat

                          by Zacks Equity Research

                          Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers

                            by Arpita Dutt

                            It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.

                              Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

                              by Zacks Equity Research

                              Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.

                                Bristol-Myers (BMY) Q3 Earnings Miss Estimates

                                by Zacks Equity Research

                                Bristol-Myers (BMY) miss estimates, however, revenues were above expectations.

                                  Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More

                                  by Zacks Equity Research

                                  Four major biotech giants are set to report third-quarter results on Oct 26. A sneak preview as to how things are shaping up for these companies.

                                    Is a Beat Likely for Pfizer (PFE) This Earnings Season?

                                    by Zacks Equity Research

                                    While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.

                                      Sweta Killa headshot

                                      Healthcare ETFs Set to Soar as Q3 Earnings Unfold

                                      by Sweta Killa

                                      With earnings surprises well in the cards, healthcare ETFs are set to soar.

                                        Will Merck (MRK) Keep the Earnings Streak Alive in Q3?

                                        by Zacks Equity Research

                                        Merck's (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q3. However, headwinds remain in the form genericization of key drugs and increasing competition.

                                          Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

                                          by Zacks Equity Research

                                          Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.

                                            Roche (RHHBY) Reports Sales Numbers for First 9 Months

                                            by Zacks Equity Research

                                            Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.

                                              Cancer Treatment Update: Second Gene Therapy Receives Approval

                                              by Zacks Equity Research

                                              The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

                                                Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

                                                by Zacks Equity Research

                                                The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

                                                  by Arpita Dutt

                                                  Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.